Lexicon Pharmaceuticals
Stock Forecast, Prediction & Price Target
Lexicon Pharmaceuticals (LXRX) stock Price Target by analysts
$6
Potential upside: 426.26%
Lexicon Pharmaceuticals price prediction
What is Lexicon Pharmaceuticals stock analysts` prediction?
Lexicon Pharmaceuticals stock forecast: Based on 1 Wall Street analysts` predicted price targets for Lexicon Pharmaceuticals in the last 3 months, the avarage price target is $6, with a high forecast of $NaN. The average price target represents a 426.26% change from the last price of $1.14.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Lexicon Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given Lexicon Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Roanna Ruiz Leerink Partners | 0% 0/1 | 11 months ago | $6 426.26% upside | $2.01 | StreetInsider | Previous targets (0) |
Yasmeen Rahimi Piper Sandler | 0% 0/1 | almost 3 years ago | $10 777.11% upside | $2.39 | TheFly | Previous targets (0) |
Unknown Citigroup | N/A | about 3 years ago | $20 1654.23% upside | $1.86 | Benzinga | N/A |
Lexicon Pharmaceuticals Financial Estimates
Lexicon Pharmaceuticals Revenue Estimates
Lexicon Pharmaceuticals EBITDA Estimates
Lexicon Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $298K N/A | $139K -53.35% | $1.20M 766.18% | Avg: $98.47M Low: $49.26M High: $162.53M avg. 8079.26% | Avg: $196.59M Low: $100.87M High: $328.67M avg. 99.63% | Avg: $350.21M Low: $179.70M High: $585.49M avg. 78.13% | Avg: $532.74M Low: $273.36M High: $890.66M avg. 52.12% |
Net Income
% change YoY
| $-88.26M N/A | $-103.12M -16.83% | $-177.11M -71.74% | Avg: $-176.40M Low: $-165.84M High: $-46.43M avg. 0.40% | Avg: $-100.64M Low: $-172.48M High: $106.14M avg. 42.94% | Avg: $30.22M Low: $11.09M High: $56.61M avg. 130.02% | Avg: $139.31M Low: $51.13M High: $260.98M avg. 360.96% |
EBITDA
% change YoY
| $-86.95M N/A | $-99.16M -14.03% | $-163.46M -64.84% | Avg: $-68.17M Low: $-112.52M High: $-34.10M avg. 58.29% | Avg: $-136.10M Low: $-227.54M High: $-69.83M avg. -99.63% | Avg: $-242.45M Low: $-405.33M High: $-124.40M avg. -78.13% | Avg: $-368.82M Low: $-616.60M High: $-189.24M avg. -52.12% |
EPS
% change YoY
| -$0.61 N/A | -$0.62 -1.63% | -$0.8 -29.03% | Avg: -$0.61 Low: -$0.75 High: -$0.21 avg. 24.19% | Avg: -$0.3 Low: -$0.78 High: $0.48 avg. 51.12% | Avg: $0.14 Low: $0.05 High: $0.26 avg. 146.10% | Avg: $0.63 Low: $0.23 High: $1.18 avg. 360.96% |
Operating Expenses
% change YoY
| $87.38M N/A | $100.89M 15.46% | $172.86M 71.32% | Avg: $10.85B Low: $5.43B High: $17.92B avg. 6180.79% | Avg: $21.67B Low: $11.12B High: $36.23B avg. 99.63% | Avg: $38.61B Low: $19.81B High: $64.55B avg. 78.13% | Avg: $58.73B Low: $30.13B High: $98.19B avg. 52.12% |
FAQ
What is Lexicon Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 133.58% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -165.84M, average is -176.40M and high is -46.43M.
What is Lexicon Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 2077.28% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $49.26M, average is $98.47M and high is $162.53M.
What is Lexicon Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 145.59% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$0.75, average is -$0.61 and high is $-0.21.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Lexicon Pharmaceuticals stock. The most successful analyst is Roanna Ruiz.